18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility: People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation therapy (SBRT) with or without androgen deprivation therapy (ADT). Design: Participants will be screened with: Medical history Physical exam Blood tests MRI Participants will have baseline MRI and PET/CT scans. For the MRI, they may get a contrast agent by IV injection. For the PET/CT scan, they will get an IV injection of 18FDCFPyL. About 1 to 2 hours later, they will get the PET/CT scan. During the scans, participants will lie on their back and remain still for 45 minutes to 1 hour. These scans will be repeated at different points during the study. Participants will get SBRT with or without ADT. Participants will complete questionnaires about their quality of life. Participants will be asked about any symptoms they are having. They will also be asked about medications they are using. They may have a physical exam. Participants will give blood and urine samples. They will give a tumor sample from a biopsy they have had in the past. After treatment, participants will have follow-up visits. These will occur 1 month after treatment, then every 3 months for a year, and then every 6 months for 1 more year.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Nowo rozpoznany rak prostaty potwierdzony biopsją
- •Brak przerzutów (raka rozprzestrzenionego na inne części ciała)
- •Planowane leczenie radiochemią (SBRT), z lub bez dodatkowego leczenia hormonalnego
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Osoby z HIV, hepatitis B lub C mogą uczestniczyć, jeśli choroba jest kontrolowana lekami
- •Chęć i możliwość podpisania dokumentu zgody na udział
✗ Disqualifies
- •Wcześniejsze leczenie raka prostaty (hormonalne, promieniowaniem lub chirurgią)
- •Rak rozprzestrzeniony na węzły chłonne lub inne organy
- •Poważne problemy z nerkami (poziom kreatyniny powyżej normy)
- •Waga powyżej 160 kg lub niemożliwość zmieszczenia się w urządzeniu do skanowania
- •Przeciwwskazania do radiochemii
- •Warunki zdrowotne, które mogłyby zakłócić badanie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 16, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Debbie-Ann N Nathan, R.N.
Deborah E Citrin, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.